ArticleDevelopmental cell2020
Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development.
Open access · bronzeAbstract read
In one paragraph
Article in Developmental cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 89 citations in OpenAlex.
- Fetal-restricted hematopoietic progenitors arise from hemogenic endothelium in vitelline and umbilical arteries.Nature cardiovascular research · 2026Article
- Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy.Cell stem cell · 2026Review
- HIDmap: a physiology-based map of human immune system development to support animal-free research and regulatory innovation.Frontiers in immunology · 2026Article
- Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity.Stem cell research & therapy · 2025Article
- Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non-Viral CAR-NK Cell Engineering.Cell proliferation · 2025Review
- The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development.Blood cancer discovery · 2025Review
- Pluripotent stem cell-based immunotherapy: advances in translational research, cell differentiation, and gene modifications.Life medicine · 2025Review
- Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy.Clinical & translational immunology · 2025Review
- RAG recombinase expression discriminates the development of natural killer cells.Frontiers in immunology · 2025Article
- Review
- Natural Killer Cells in Cancers of Respiratory System and Their Applications in Therapeutic Approaches.Immunity, inflammation and disease · 2024Review
- Efficient generation of human NOTCH ligand-expressing haemogenic endothelial cells as infrastructure for in vitro haematopoiesis and lymphopoiesis.Nature communications · 2024Article
- Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34Stem cell research & therapy · 2024Article
- CD32 captures committed haemogenic endothelial cells during human embryonic development.Nature cell biology · 2024Article
- Characterization of gene regulatory networks underlying key properties in human hematopoietic stem cell ontogeny.Cell regeneration (London, England) · 2024Article
- Article
- Comparative analysis of iPSC-derived NK cells from two differentiation strategies reveals distinct signatures and cytotoxic activities.Frontiers in immunology · 2024Article
- Macrophage Development and Function.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Review
- Engineered hematopoietic and immune cells derived from human pluripotent stem cells.Experimental hematology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Carissa DegeDepartment of Medicine, Division of Hematology, Washington University in St Louis, St. Louis, MO 63110, USA.
Katherine H FeganCenter for Pediatric Biomedical Research and Department of Pediatrics, University of Rochester, Rochester, NY 14642, USA.
J Philip CreamerDepartment of Medicine, Division of Hematology, Washington University in St Louis, St. Louis, MO 63110, USA.
Melissa M Berrien-ElliottDepartment of Medicine, Division of Oncology, Washington University in St Louis, St. Louis, MO 63110, USA.
Stephanie A LuffDepartment of Medicine, Division of Hematology, Washington University in St Louis, St. Louis, MO 63110, USA.
Darren KimDepartment of Medicine, Division of Hematology, Washington University in St Louis, St. Louis, MO 63110, USA.
Julia A WagnerDepartment of Medicine, Division of Oncology, Washington University in St Louis, St. Louis, MO 63110, USA.
Paul D KingsleyCenter for Pediatric Biomedical Research and Department of Pediatrics, University of Rochester, Rochester, NY 14642, USA.
Kathleen E McGrathCenter for Pediatric Biomedical Research and Department of Pediatrics, University of Rochester, Rochester, NY 14642, USA.
Todd A FehnigerDepartment of Medicine, Division of Oncology, Washington University in St Louis, St. Louis, MO 63110, USA.
James PalisCenter for Pediatric Biomedical Research and Department of Pediatrics, University of Rochester, Rochester, NY 14642, USA. Electronic address: james_palis@urmc.rochester.edu.
Christopher M SturgeonDepartment of Medicine, Division of Hematology, Washington University in St Louis, St. Louis, MO 63110, USA; Department of Developmental Biology, Washington University in St Louis, St. Louis, MO 63110, USA; Center of Regenerative Medicine, Washington University in St Louis, St. Louis, MO 63110, USA. Electronic address: csturgeon@wustl.edu.
Washington University in St. Louis · USUniversity of Rochester · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6MPRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYT32HL007088 · NHLBI · WASHINGTON UNIVERSITY · PI Grant Anthony Challen, Stephen Oh · 1985 to 2026
$14.1MWashington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7MTRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPYR01CA205239 · NCI · WASHINGTON UNIVERSITY · PI FEHNIGER, TODD A · 2017 to 2020
$2.4MMesodermal Commitment of the Definitive Hematopoietic ProgramR01HL145290 · NHLBI · WASHINGTON UNIVERSITY · PI STURGEON, CHRISTOPHER MICHAEL · 2019 to 2023
$2.1MInitiation of Mammalian Embryonic HematopoiesisR01DK079361 · NIDDK · UNIVERSITY OF ROCHESTER · PI PALIS, JAMES · 2007 to 2012
$1.5MNCATS NIH HHS UL1 TR002345NCI NIH HHS K12 CA167540NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R01 CA205239NHLBI NIH HHS R01 HL145290NHLBI NIH HHS T32 HL007088NIDDK NIH HHS R01 DK079361
Abstract
Natural killer (NK) cells are a critical component of the innate immune system. However, their ontogenic origin has remained unclear. Here, we report that NK cell potential first arises from Hoxa
Indexed as
Cell DifferentiationCell LineageAnimalsEmbryonic Stem CellsErythroid Precursor CellsFemaleHematopoiesisHematopoietic Stem CellsHumansKiller Cells, NaturalMaleMiceMyeloid Progenitor CellsYolk Sacadoptive immunotherapydefinitive hematopoiesisEMPerythro-myeloid progenitorHSC-independenthuman pluripotent stem cellsnatural killer cellsontogenyprimitive hematopoiesisyolk sac
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.